Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus;Eficacia y seguridad de empagliflozina en combinación con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2

Endocrinologia y Nutricion

Volumn 63, Issue 10, 2016, Pages 519-526

  Romera, Irene ^a   Ampudia Blasco, Francisco Javier ^b   Pérez, Antonio ^c   Ariño, Bernat ^d   Pfarr, Egon ^e   Giljanovic Kis, Sanja ^f   Naderali, Ebrahim ^g,h  

^a ELI LILLY AND COMPANY   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d Boehringer Ingelheim Pharma GmbH Co   (Spain)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f Eli Lilly (Suisse) SA Representative Office   (Croatia)

^g ELI LILLY AND COMPANY   (United States)

^h LIVERPOOL HOPE UNIVERSITY   (United Kingdom)

Author keywords

Empagliflozin; SGLT 2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; AGED; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DISEASE PREDISPOSITION; FEMALE; INFECTION; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

AGED; BENZHYDRYL COMPOUNDS; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFECTION; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84994409150     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2016.06.003     Document Type: Article

References (25)

1. 1 Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
2. 2 Brown, J.B., Conner, C., Nichols, G.A., Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 33 (2010), 501–506.
3. 3 Cook, M.N., Girman, C.J., Stein, P.P., Alexander, C.M., Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 24 (2007), 350–358.
4. 4 Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R., Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 (1999), 2005–2012.
5. 5 Piya, M.K., Tahrani, A.A., Barnett, A.H., Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol 70 (2010), 631–644.
6. 6 Campbell, R.K., Fate of the beta-cell in the pathophysiology of type 2 diabetes. J Am Pharm Assoc (2003) 49:Suppl 1 (2009), S10–S15.
7. 7 Matthews, D.R., Cull, C.A., Stratton, I.M., Holman, R.R., Turner, R.C., UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15 (1998), 297–303.
8. 8 Perez, A., Mediavilla, J.J., Minambres, I., Gonzalez-Segura, D., Glycemic control in patients with type 2 diabetes mellitus in Spain. Rev Clin Esp 214 (2014), 429–436.
9. 9 Kovacs, C.S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H.J., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2014), 147–158.
10. 10 Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D.E., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
11. 11 JARDIANCE® Summary of product characteristics, December 2014 [consultado 4 Dic 2015]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000285/WC500021386.pdf.
12. 12 Haring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U.C., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
13. 13 Haring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H.J., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
14. 14 Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
15. 15 Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E., Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 16 (2014), 38–47.
16. 16 Sun, Y.N., Zhou, Y., Chen, X., Che, W.S., Leung, S.W., The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomised controlled trials. BMJ Open, 4, 2014, e004619.
17. 17 Yang, X.P., Lai, D., Zhong, X.Y., Shen, H.P., Huang, Y.L., Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 70 (2014), 1149–1158.
18. 18 Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H.J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
19. 19 Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H.J., et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36 (2013), 4015–4021.
20. 20 Ferrannini, E., Seman, L., Seewaldt-Becker, E., Hantel, S., Pinnetti, S., Woerle, H.J., A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15 (2013), 721–728.
21. 21 Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S.S., Meier, C.R., Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested case-control analysis. Diabetes Care 31 (2008), 2086–2091.
22. 22 Ng, J.M., Mellor, D.D., Masson, E.A., Allan, B.J., Sulphonyurea as a cause of severe hypoglycaemia in the community. Prim Care Diabetes 4 (2010), 61–63.
23. 23 Phung, O.J., Scholle, J.M., Talwar, M., Coleman, C.I., Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303 (2010), 1410–1418.
24. 24 Halimi, S., Verges, B., Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 40:6 Suppl 1 (2014), S28–S34.
25. 25 Lamos, E.M., Younk, L.M., Davis, S.N., Canagliflozin an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 9 (2013), 763–775.